Mesoblast (MESO) Posts Q1 Loss of 5c/Share
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Mesoblast (NASDAQ: MESO) reported Q1 EPS of ($0.05), $0.30 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $395 thousand versus the consensus estimate of $3.69 thousand.
In line with previous guidance, the Company implemented operational streamlining measures during the quarter while achieving, and continuing to maintain progress towards, key milestones in its Tier 1 clinical programs.
For earnings history and earnings-related data on Mesoblast (MESO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Herbalife (HLF) Provides Q4, FY17 Guidance in Memorandum for $1.325B Credit Facility; Lowers FY17 Sales Guidance
- DryShips (DRYS) Acquires Its First VLGC With 5 Year Time Charter Attached to Oil Major
- P&G raises FY organic sales growth forecast after sales beat
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!